---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-084760"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2026-07-18T00:41:06+00:00"
generated_at: "2026-07-20T10:05:27.394223+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# VYNE stockholders approve all proposals for merger with Yarrow Bioscience at special meeting

## Summary
- Proposal 1 (issuance of shares >20% and change of control) approved: 15,915,017 for, 137,159 against.
- Proposal 2 (reverse stock split 1:10-70) approved: 25,389,760 for, 550,694 against.
- Proposal 3 (increase authorized shares from 150M to 300M) approved: 23,921,348 for, 2,013,526 against.
- Proposal 4 (Yarrow 2026 Stock Incentive Plan) approved: 12,691,384 for, 3,358,164 against.
- Proposal 5 (Yarrow 2026 Employee Stock Purchase Plan) approved: 13,131,018 for, 2,909,493 against.

## SEC filing metadata
- accession: 0001104659-26-084760
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2026-07-18T00:41:06+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000110465926084760/0001104659-26-084760-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000110465926084760/tm2620687d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-084760
- JSON: https://secwatch.observer/filing/0001104659-26-084760.json
- Plain text: https://secwatch.observer/filing/0001104659-26-084760.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.